Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789920 | 0.90 | KDR (0.48) | KDRNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1789248 | 0.87 | KDR (0.43) | KDRNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1788662 | 0.86 | KMT2A (0.53) | KDRNPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1786747 | 0.83 | KDR (0.66) | KDRNPC1TSHRALDH1A1KDM4E | |
| SCHEMBL1789590 | 0.83 | MEN1 (0.49) | KDRALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1784588 | 0.83 | KDR (0.62) | KDRNPC1TSHRALDH1A1KDM4E | |
| SCHEMBL1788101 | 0.83 | NPC1 (0.40) | KDRNPC1ALDH1A1KDM4ELMNA | |
| SCHEMBL1788133 | 0.82 | ALDH1A1 (0.54) | NPC1ALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL1785017 | 0.79 | KDR (0.74) | KDRNPC1TSHRALDH1A1KDM4E | |
| SCHEMBL1788425 | 0.79 | KDR (0.57) | KDRNPC1TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8507485-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-7906511-B2 | Cyclic compound having pyrimidinylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | SATEN PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1864977-A1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291951-A1 | Novel Cyclic Compound Having Pyrimidinylalkylthio Group | AGTR1, AGTR2, ARRB1 | KDR 2531/4885NPC1 1451/4885TSHR 511/4885 |
| US-20110124646-A1 | Novel cyclic compound having pyrimidinylalkylthio group | FLT1, VEGFA, FLT4 | KDR 4/4885NPC1 1069/4885TSHR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.